Purpose The purpose of this study was to compare the confirmation rate of day-3 embryo biopsy (blastomere) and trophectoderm biopsy using array-comparative genomic hybridization (array-CGH) technology. Methods A blinded study was conducted to re-analyse 109 embryos previously diagnosed as chromosomally abnormal by array-CGH. Preimplantation genetic screening (PGS) was performed using array-CGH on day 3 (n=50) or day 5 (n=59). Partial chromosome gains or losses were excluded (n=6), and only whole chromosome aneuploidies were considered. Reanalysis of whole blastocysts was carried out following the same array-CGH protocol used for PGS. Results The PGS result was confirmed in the whole blastocyst in (a) 49/50 (98 %) abnormal embryos after day-3 biopsy and (b) 57/59 (96.6 %) abnormal embryos after trophectoderm biopsy. One embryo (1/50; 2 %) was diagnosed as abnormal, with monosomy 18, on day 3, and software analysis of the whole blastocyst gave a euploid result; however, a mosaic pattern was observed for monosomy 18 in the whole blastocyst. Two trophectoderm biopsy cases (3.4 %) did not have the abnormalities (trisomy 7, and trisomy 1 and 4, respectively) verified in the whole embryo. Concordance rates for both biopsy strategies and for individual chromosomes were evaluated by Fisher's exact test and showed no significant differences. Conclusions Both types of biopsies showed similar high concordance rates with whole blastocyst results. Therefore, regarding the confirmation rates shown in this work, day-3 embryo biopsies can be representative of the whole embryo and both types of biopsy can be used for clinical analysis in PGS following the described array-CGH protocol.
Introduction
Preimplantation genetic screening (PGS) is an early method to detect aneuploidies in preimplantation embryos. Those embryos diagnosed as chromosomally abnormal will be discarded, while chromosomally normal embryos will be candidates for transfer to the maternal uterus. Historically, in in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatments, embryos have been selected for transfer using some morphological parameters as well as their in vitro development. The introduction of PGS in IVF settings enables embryos to be selected first by their chromosomal status and second by morphology and development status among the chromosomally normal ones. PGS can be offered to patients with an increased risk of having a higher percentage of chromosomally abnormal embryos, with the aim of improving their reproductive outcome. By transferring only chromosomally normal embryos, pregnancy and implantation rates are expected to be higher and miscarriage rates are expected to be lower, due to the reduced likelihood of implantation of chromosomally abnormal embryos (mainly embryos lacking one or more chromosomes) and because about 50-60 % of miscarriages in the first trimester result from chromosomal abnormalities in the foetus [1, 2] . The most common clinical indications for PGS include patients with advanced maternal age (AMA), recurrent pregnancy-loss couples (RPL), couples having repetitive implantation failures (RIF), and severe male-factor infertility cases (SMF). Moreover, any couple having a previous known aneuploid pregnancy can be counselled to undergo PGS during subsequent attempts.
Currently, array-comparative genomic hybridization (CGH) is the technique most commonly used for PGS; quantitative fluorescence-polymerase chain reaction (QF-PCR) and singlenucleotide polymorphism (SNP) array are also used. Recently, next-generation sequencing (NGS) has emerged as a promising technique for PGS [3, 4] . Independently of the technique applied, there is a common agreement that screening methods that include all 24 chromosomes must provide robust and reliable results with low false-positive and false-negative rates no higher than 1-3 %, as well as a Bno-calling^rate lower than 2 % [3, 5] .
For any screening method, the genetic material is obtained through embryo biopsy. Three approaches are available: polar body biopsy (requires the analysis of both first and second polar bodies, retrieved on the day of fertilization), blastomere biopsy or cleavage-stage biopsy (single-cell day-3 embryo biopsy), and trophectoderm biopsy (day-5 and/or day-6 embryo biopsy). Polar body biopsy has been used in preimplantation analysis [6, 7] and provides only maternal genetic information. Day-3 embryo biopsies enable a fresh embryo transfer of blastocysts on day 5 of the same cycle. In contrast, trophectoderm biopsies require embryo vitrification and embryo transfer in a subsequent cycle, or a day-5 embryo biopsy along with a day-6 fresh embryo transfer.
Currently, blastomere and trophectoderm biopsies are the two main approaches used for PGS, but there is a trend towards trophectoderm biopsies. Day-3 embryo biopsy has been highly criticized because of a high degree of mosaicism in cleavagestage embryos and the possibility of self-correction of aneuploidies from cleavage to blastocyst stage; therefore, trophectoderm biopsy has been suggested as the most reliable option for PGS [8] . At this stage, the embryos have undergone their first cellular differentiation resulting in two cell lineages: the inner cell mass (the cells that will form the embryo) and the trophectoderm cells (that will form the extraembryonic tissues). Thus, the biopsy of trophectoderm cells would not adversely affect embryo development. Moreover, the identical genetic constitutions of both groups of cells from the same embryo have been demonstrated [9, 10] .
The aim of this work is to compare the confirmation rate of PGS results obtained on day-3 embryo biopsies (cleavage stage) and blastocyst biopsies (trophectoderm biopsy) using the same array-CGH protocol. Thus, the usefulness of both embryo biopsy strategies for PGS will be tested from the genetic point of view.
Materials and methods
A blinded study was performed to re-analyse 115 embryos from a PGS programme, originally diagnosed as chromosomally abnormal by array-CGH technique. Embryos having partial chromosome gains and losses were excluded from the study, since at the moment of collecting data for the study there was no consensus about the clinical impact of these unbalances, and only whole chromosome aneuploidies were considered. Six embryos (5.2 %) that were carriers of a segmental imbalance were excluded from the study. A total of 109 blastocysts from 58 patients were included in the study. Embryo biopsy was performed either on day 3 (26 patients, mean female age of 38.6) or day 5 (32 patients, mean female age of 36.9). The day-5 embryo biopsy was performed on cases with ≥12MII oocytes or with ≥6 good-quality embryos on day 3; in the rest of the cases, day-3 embryo biopsy was performed. Following these criteria, PGS was performed on day-3 biopsies in 50 out of the 109 embryos, and on day-5 biopsies in the remaining 59 embryos. Re-analysis of the whole 109 blastocysts was carried out following the same array-CGH protocol used for PGS. The manufacturer's array-CGH scoring criteria were used to define embryos as euploid or aneuploid (BlueGnome Ltd., Cambridge, UK). After scoring the re-analysed blastocysts, array-CGH results were compared between the embryo biopsy and the whole blastocyst of the same embryo, first for the chromosomal status of the embryo and second for the confirmation rates per individual chromosome. Regarding the chromosomal status of the embryo, re-analysed embryos were divided according to previously described categories in Delhanty et al. [11] as normal, uniformly aneuploid, mosaic diploid-aneuploid, mosaic aneuploid and chaotic. In addition, the group of mosaic aneuploid re-analysed embryos were further analysed and divided into three groups according to their results per chromosome: (i) group A comprises embryos having not all but at least one of the aneuploidies present in the biopsy; group B comprises chromosomally abnormal embryos showing a complementary aneuploidy for a given chromosome (e.g. monosomy versus trisomy); and group C comprises embryos for which all aneuploidies present in the biopsy were observed plus any additional aneuploidies.
The present study has been approved by the CEIC (Spanish ethical committee of clinical investigation). It is a biomedical study not implying any contact with human beings (only embryo biopsies); moreover, in this blinded study, all the samples were anonymized before re-analysis.
All patients included in the study signed a consent form that includes all the possible pitfalls that may happen in PGS analysis and the possibility for re-analysis of the abnormal embryos. In all the cases, patients underwent controlled ovarian stimulation using standardized protocols and ICSI was performed [12] . Fertilization was assessed about 17-20 h after ICSI, and embryo development was recorded every 24 h until the day of embryo transfer. Embryos were cultured in IVF/ CCM medium (Vitrolife, Göteborg, Sweden) until day 3 of embryo development, then cultured in CCM medium in a coculture with a monolayer of endometrial epithelial cells until day 5 [13] . For the cases of day-3 embryo biopsy, only embryos with five or more nucleated blastomeres and less than 25 % fragmentation degree were biopsied. Day-3 embryo biopsy can be summarized as follows: embryos were placed on a droplet containing Ca 2+ /Mg 2+ -free medium (G-PGD, Vitrolife, Göteborg, Sweden/LifeGlobal, Guilford, CT), the zona pellucida was perforated by pulses of laser (OCTAX, Herborn, Germany), and one blastomere was withdrawn from each embryo. Then, individual blastomeres were placed in 0.2-mL PCR tubes containing 2 μL PBS. For blastomere washing and handling, 1 % polyvinylpyrrolidone (PVP) was used. Euploid embryos were candidates to be transferred on day 5, and surplus euploid embryos were vitrified either on day 5 or on day 6. For the cases of trophectoderm biopsy, embryos were biopsied using CCM medium. Laser technology was used to perform the biopsy by using about four to six laser pulses to cut the trophectoderm cells inside the aspiration pipette. Then, trophectoderm biopsies were placed in 0.2-mL PCR tubes containing 2 μL PBS by the same washing in PVP drops than for day-3 biopsies. Also, the same washing method using PVP was performed to introduce whole day-5 blastocysts to be re-analysed.
To analyse all the three types of samples (blastomere biopsies, trophectoderm biopsies and whole blastocysts), the same array-CGH platform was used (24sure® v.3 platform; BlueGnome Ltd., Cambridge, UK). This platform was previously validated in our laboratory before being applied for clinical purposes [14] . A whole genome amplification (WGA) protocol was performed in all individual samples (Sureplex®; BlueGnome Ltd. Cambridge, UK). After WGA, the same 24-h array-CGH protocol was performed, including DNA labelling, hybridization, washing, scanning and data analysis (24sure® v.3 platform; BlueGnome Ltd. Cambridge, UK). Embryos were diagnosed as chromosomally normal, abnormal or chaotic abnormal. Chaotic embryos were defined as those showing a complex pattern of aneuploidies, involving more than six chromosomes, as previously described [14] . For the analysis of whole blastocyst samples, the presence of mosaicism was predicted according to the Log 2 ratio results obtained in a previous experimental study using the same array-CGH platform where mosaic blastocyst samples were simulated using groups of 100 cells, mixing euploid and aneuploid cells within the following ratios: 0:100, 25:75, 50:50, 75:25 and 100:0 [15] . The array-CGH manufacturer establishes a Log 2 ratio threshold of ±0.3 for a result to be considered normal (taking into account the average Log 2 ratio deviation ranging from 0.07 to 0.15). In the experimental study, when samples had 25 % of abnormal cells, the Log 2 ratio was increased but not above the 0.3 threshold; with 50 % of abnormal cells, the Log 2 ratio was always above the 0.3 threshold, and with 100 % of abnormal cells, the Log 2 ratio was 0.4 (with standard deviation of 0.08 to 0.1) [15] .
Results
After comparison of the array-CGH results on embryo biopsies and in the whole blastocyst of the corresponding embryo, the overall confirmation rate for day-3 embryo biopsies was 98 % (49/50) and 96.6 % (57/59) for trophectoderm biopsies. In detail, for day-3 embryo biopsies, 37/50 (74 %) embryos were uniformly aneuploid, 12/50 (24 %) were consistent with a mosaic aneuploid pattern and only one blastocyst (1/50; 2 %) was diagnosed as euploid by software analysis. However, the re-analysis of the whole blastocyst showed a profile compatible with mosaicism for the same monosomy 18 observed in the original biopsy (Fig. 1) . This embryo was considered as euploid-aneuploid mosaic because the average Log 2 ratio for chromosome 18 was −0.34. This would be the only case considered a false-positive, yielding a 2 % (1/50) false-positive rate for array-CGH in day-3 embryo biopsies. Among the 12 embryos showing a mosaic aneuploid pattern, in 6/50 (12 %), not all but at least one day-3 aneuploidy was still present in the whole embryo (group A); in 4/50 (8 %) whole blastocysts, the complementary aneuploidy for a given chromosome (e.g. monosomy versus trisomy) was present (group B); and in two of them, 2/50 (4 %), all aneuploidies present in the biopsy were observed in the re-analysed blastocyst but also an additional chromosome loss was detected (group C).
For trophectoderm embryo biopsies, 48/59 (81.4 %) embryos were uniformly aneuploid, 9/59 (15.2 %) were consistent with a mosaic aneuploid pattern and only two embryos were euploid (2/59; 3.4 %). None of the abnormalities present on the trophectoderm biopsies for these two embryos (trisomy 7 and trisomy 1 and 4, respectively) were observed in the blastocyst analysis (Fig. 2) . Therefore, the false-positive rate for array-CGH in trophectoderm biopsies in this study was 3.4 %. Among the nine embryos showing a mosaic aneuploid pattern, in 7/59 (11.9 %), at least one aneuploidy observed in the trophectoderm biopsy was still present in the blastocyst analysis (group A), and in 2/59 (3.4 %) cases, the whole blastocyst showed a complementary aneuploidy for a given chromosome (group B). There was no embryo in group C category showing any additional aneuploidies in the whole blastocyst compared to trophectoderm biopsies. Statistical analysis of the results in each subgroup for both biopsy strategies evaluated by Fisher's exact test showed no significant differences in any case (Table 1) .
Regarding confirmation rates per individual chromosomes, most of the chromosomes showed 100 % concordance in both types of biopsies. In fact, the overall confirmation rate per individual chromosome was 98.8 % for day-3 embryos (ranging from 94 to 100 %) and 98.5 % for trophectoderm biopsies (93.2 to 100 %). The lowest confirmation rate in day-3 cases was 94 % for chromosome 22, and in trophectoderm biopsies, the lowest was 93.2 % for chromosome 13 (Table 2) , but no statistical differences were observed for any of the chromosomes.
Discussion
This study shows high and similar confirmation rates of PGS results when re-analysing the whole blastocyst in both types of embryo biopsy strategies tested (blastomere and trophectoderm biopsies). Moreover, the confirmation rate per individual chromosome was also very high.
Any technique selected for the screening of all 24 chromosomes in PGS should offer reliable and timely results. Furthermore, every technique should be applied in clinical programmes only after their validation using a wellestablished technique. Array-CGH platforms were tested by comparing them to the fluorescence in situ hybridization (FISH) technique before applying array-CGH for clinical diagnosis. Those studies showed a very low number of embryos with Bno results^(from 1.4 to 2.9 %) as well as low false-
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Mosaic day-5 embryo: monosomy 18/euploid Day-5 arrayCGH of the whole embryo Fig. 1 The no concordant result for day-3 embryo biopsy cases compared to re-analysis of the whole blastocyst. The top image shows the array-CGH result of the day-3 embryo biopsy sample (result: 45,XX,-18). The bottom image corresponds to the array-CGH profile of the whole blastocyst analysis from the same embryo (result: software analysis gives a euploid result; however, a pattern of mosaic 46,XX/45,XX,-18 can be observed, and the Log 2 ratio Ch1/Ch2 is −0.38, and it can be considered as abnormal below −0.40) positive rates, from 1.9 to 2.7 %, when comparing the array-CGH result of the biopsy to the reconfirmation results of the remaining cells of the day-5 embryos using FISH technique [14, 16, 17] . Array-CGH has been applied for PGS mainly in day 3 and in trophectoderm biopsies. The number of PGS cycles performed using trophectoderm biopsies is increasing worldwide compared to the number of PGS cycles following day-3 embryo biopsies. This trend towards trophectoderm biopsies for PGS can be explained mainly by improved embryo culture conditions that allow a higher number of good-quality blastocysts to be biopsied and also by improved vitrification systems [18] that provide nearly 100 % embryo survival after the freezing/thawing process. Moreover, day-3 embryo biopsy was highly criticized in favour of trophectoderm biopsy because of a high degree of embryo mosaicism at the cleavage stage, as well as some potential for aneuploidy self-correction during embryo development, implying that a more accurate analysis would result if biopsy was performed on trophectoderm rather than on day-3 embryos [8] . However, the present work shows a very high confirmation rate per individual chromosome in both types of embryo biopsies (98.8 % for day 3 versus 98.5 % for trophectoderm), and these rates are also reflected in high confirmation rates of the PGS diagnosis per embryo (98 % for day 3 versus 97.6 % for trophectoderm).
The latest RCT performed in male-factor patients using the strategy of performing the array-CGH technique on day-3 embryo biopsies and fresh embryo transfer on day 5 shows an ongoing pregnancy rate per PGS cycle of 66.7 %, statistically superior to the ongoing pregnancy rate of the control group of male-factor patients without PGS (42.8 %) [19] . Similarly, another RCT using array-CGH on trophectoderm biopsies presents an ongoing pregnancy rate of 69.1 % in young good-prognosis patients that underwent PGS compared to 41.7 % in patients of the same age range but without PGS [20] . Statistically significant higher pregnancy rates are achieved in both types of biopsies, day-3 and trophectoderm, when comparing PGS with the control group. Therefore, the most feasible scenario is that any harm caused by embryo biopsies would be overcome by the selection of a euploid embryo after PGS, at least in these studies.
The present work shows low discrepancy rates between the PGS result of the biopsy and the re-analysis result of the rest of the blastocysts. Only one (1/50, 2 %) of the embryos biopsied on day 3 showed results consistent with a mosaic Beuploidaneuploid^pattern, and only two (2/59, 3.4 %) of the embryos biopsied on day 5 showed results consistent with a mosaic Beuploid-aneuploid^pattern. The low rate of Beuploidaneuploid^mosaic blastocysts is similar to the rate shown in Capalbo et al. [10] where 70 blastocysts diagnosed as chromosomally abnormal by array-CGH on trophectoderm biopsies were re-analysed. In that study, isolated cells from the inner cell mass as well as from the trophectoderm were reanalysed using FISH, and discrepancies were found in 11 out of 70 blastocysts (15.7 %) compared to array-CGH analysis in embryo biopsies. However, only in two cases (2/70; 2.9 %) were blastocysts classified as mosaic Beuploid-aneuploid^.
It is challenging to calculate the real incidence of mosaicism in preimplantation embryos. A study comparing SNPmicroarray versus FISH technique for the analysis of individual blastomeres from the same day-3 embryo showed more reliable results for SNP-microarray (96 versus 83 %) and also a lower mosaicism degree (31 %) for SNP-microarray samples. Therefore, the authors suggested that the incidence of mosaicism may have been overestimated in previous studies due to technical inconsistency of the FISH technique rather than any biological phenomena [21] . However, microarray techniques have also the limitation that they can detect mosaicism only if it represents more than 25-40 % of the cells [15, 22, 23] . The embryo biopsy will always represent a small percentage of the total number of cells of the embryo, both for day 3 and trophectoderm, and only chromosomally abnormal embryos can be re-analysed. Most likely, some of those transferred as Bchromosomally normal embryos^may be carrying some abnormal cells. Therefore, two main types of mosaic embryos can be found: Baneuploid-aneuploid^mosaic, having all chromosomally abnormal cells but with different cell lines, and Beuploid-aneuploid^mosaic, having some normal cells and some abnormal cells. Initially, all the Baneuploid-aneuploid^mosaic embryos will not be candidates for transfer; therefore, the group of Beuploid-aneuploidm osaics are the ones that can create concern in this matter, mainly depending on the percentage of normal versus abnormal cells they may have.
In most of these studies as well as in ours, euploid embryos cannot be re-analysed due to law restrictions; therefore, some Beuploid-aneuploid^mosaic embryos could be missed if the biopsy would contain only chromosomally normal cells. Nevertheless, looking at the clinical outcome of patients undergoing PGS with array-CGH, which shows high pregnancy and implantation rates as well as a reduced miscarriage rate [3, 24, 25] , and also at the very low clinically recognizable error rate shown in PGS [5] , it can be assumed that the number of Beuploid-aneuploid^mosaic embryos in cleavage and blastocyst stage should not be very high and should not have a major clinical impact.
In summary, according to the results shown and discussed in the present paper, both types of embryo biopsy, day-3 and trophectoderm biopsies, are feasible approaches that can be used if required in a PGS program. Day-3 PGS could be offered for those patients with lower-quantity and/or lowerquality embryos. Therefore, both types of embryo biopsies can coexist in the same PGS program and the patient's treatment can be customized according to the individual patient's requirements.
Conclusions
Both day-3 and trophectoderm embryo biopsies showed similar concordance rates with whole blastocyst results. Therefore, regarding the confirmation rate, day-3 embryo biopsies can be representative of the whole embryo and both types of biopsy can be used for clinical analysis in PGS following the described array-CGH protocol.
